IP Library Granted Patent US 12,173,288
Granted Patent B2
US 12,173,288 · App. 17/062,422 · Granted Dec 24, 2024

Oligonucleotide-ligand conjugates and process for their preparation

Inventors: Muthiah Manoharan (Cambridge, MA); Jayaprakash K. Nair (Cambridge, MA); Pachamuthu Kandasamy (Cambridge, MA); Shigeo Matsuda (Cambridge, MA); Alexander V. Kelin (Cambridge, MA); Muthusamy Jayaraman (Cambridge, MA); Kallanthottathil G. Rajeev (Cambridge, MA)
Assignee: ALNYLAM PHARMACEUTICALS, INC.
C12N15/113A61K47/549C07H21/00C12N15/111C12N2310/14C12N2310/351C12N2320/30C12N2320/32C12N2330/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,173,288
App. No.
17/062,422
Granted
Dec 24, 2024
Kind
B2
Abstract

The present invention relates to ligand conjugates of oligonucleotides (e.g., iRNA agents) and methods for their preparation. The ligands are derived primarily from monosaccharides These conjugates are useful for the in vivo delivery of oligonucleotides.

Claims (10)

1. A double-stranded siRNA compound capable of mediating silencing of a target RNA, comprising an oligonucleotide conjugate, wherein each of nucleosides at the 7 th , 8 th and 9 th position from the 3′-end of the oligonucleotide is conjugated to a carbohydrate-containing ligand at its 2′-position, wherein the conjugated nucleoside has the formula:

where

the 5′ and 3′ ends are each attached to another nucleoside of the oligonucleotide or to a terminus;

each occurrence of R 6 is independently a nucleobase; and

—R 7 —(R 8 ) n represents the structure

2. The double-stranded siRNA compound of claim 1 , wherein the double stranded portion of the double stranded siRNA compound ranges 19 to 23 nucleotides pairs in length.

3. The double-stranded siRNA compound of claim 1 , wherein the oligonucleotide conjugate further comprises one or more nucleotides having a 2′-F or 2′-OCH 3 group.

4. The double-stranded siRNA compound of claim 1 , comprising a sense strand and an antisense strand, wherein the oligonucleotide conjugate is the sense strand.

5. The double-stranded siRNA compound of claim 4 , wherein the sense strand is 14-50 nucleotides in length.

6. The double-stranded siRNA compound of claim 1 , wherein the double-stranded siRNA compound is sufficiently large that it can be cleaved by Dicer to produce a smaller siRNA compound.

Assignments (2)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2024
From: MANOHARAN, MUTHIAH; NAIR, JAYAPRAKASH K; KANDASAMY, PACHAMUTHU; MATSUDA, SHIGEO; KELIN, ALEXANDER V; JAYARAMAN, MUTHUSAMY; RAJEEV, KALLANTHOTTATHIL G
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 066203/0634 →